RESUMEN
Objective To study the correlation analysis of mecobalamin in treatment of diabetic peripheral neuropathy and its plasma homocysteine level. Methods 100 patients were selected from January 2013 to August 2016 treatment of diabetic peripheral neuropathy, according to admission ID, were randomly divided into control group and observation group, each group of 50 people. At the same time, 50 healthy persons were collected as normal control group and two groups were given routine treatment of Western medicine. The observation group was given mecobalamin. The plasma levels of plasma homocysteine were detected in the three groups, and the improvement degree of neuropathy was assessed by clinical and electrophysiological methods. Results The observation group and the control group of patients before treatment, plasma homocysteine levels were significantly higher than normal control group; the observation group with Mecobalamin after treatment of plasma homocysteine level in patients were significantly better than the control group (P<0.05); through clinical and electrophysiological evaluation method of observation group of patients in the neuropathic symptoms and nerve conduction velocity is the control group improved significantly (P<0.05). Conclusion The levels of plasma homocysteine and diabetic peripheral neuropathy have a strong correlation, and the use of mecobalamin in treating diabetic peripheral neuropathy can decrease homocysteine levels in patients with, and is effective for the treatment of diabetic peripheral neuropathy, and can be widely applied in clinical treatment.
RESUMEN
Objective To study the correlation analysis of mecobalamin in treatment of diabetic peripheral neuropathy and its plasma homocysteine level. Methods 100 patients were selected from January 2013 to August 2016 treatment of diabetic peripheral neuropathy, according to admission ID, were randomly divided into control group and observation group, each group of 50 people. At the same time, 50 healthy persons were collected as normal control group and two groups were given routine treatment of Western medicine. The observation group was given mecobalamin. The plasma levels of plasma homocysteine were detected in the three groups, and the improvement degree of neuropathy was assessed by clinical and electrophysiological methods. Results The observation group and the control group of patients before treatment, plasma homocysteine levels were significantly higher than normal control group; the observation group with Mecobalamin after treatment of plasma homocysteine level in patients were significantly better than the control group (P<0.05); through clinical and electrophysiological evaluation method of observation group of patients in the neuropathic symptoms and nerve conduction velocity is the control group improved significantly (P<0.05). Conclusion The levels of plasma homocysteine and diabetic peripheral neuropathy have a strong correlation, and the use of mecobalamin in treating diabetic peripheral neuropathy can decrease homocysteine levels in patients with, and is effective for the treatment of diabetic peripheral neuropathy, and can be widely applied in clinical treatment.